FcRn normally rescues IgG antibodies from intracellular destruction and returns them to circulation. Blocking that recycling pathway accelerates IgG clearance, including pathogenic autoantibodies, without directly eliminating the B cells that produced them.
Cytrellis has commercially launched ellacor in Australia after TGA registration of its Class IIa handpiece and cartridge, opening a broader body-resurfacing market for its nonthermal Micro-Coring platform.
The prospective NEURO PMR study found 92% blinded concordance between portable and conventional brain MRI, rising to 98% after clinical review, as Hyperfine reports more than 3,000 office scans.
FDA has accepted Kowa’s NDA for NCX 470 and set an April 30, 2027 PDUFA date after two Phase 3 trials established noninferiority to latanoprost in lowering intraocular pressure.
FDA raised no objection to a randomized Phase 3 comparing neoadjuvant ruxotemitide plus pembrolizumab with pembrolizumab alone and indicated that one well-controlled study could potentially support an NDA.
Radiofrequency burns and cryoballoon freezes cardiac tissue to isolate pulmonary veins. Pulsed field ablation instead uses microsecond electrical pulses to disrupt myocardial cells, offering a nonthermal route that may reduce collateral injury while delivering comparable rhythm control.
Soquelitinib shows durable T-cell lymphoma responses and 28.1-month median survival as Corvus Pharmaceuticals advances its Phase 3 trial.
PENTAX Medical will integrate and distribute MAGENTIQ-COLO across the US, EMEA, JAPAC and Latin America after randomized evidence showed higher adenoma detection and a lower miss rate than conventional colonoscopy.
MolDX coverage now includes RaDaR ST for monitoring immune-checkpoint inhibitor response in late-stage solid tumors, expanding reimbursement while current ASCO guidance still treats ctDNA as complementary rather than a replacement for standard assessment.
SK Biopharmaceuticals is acquiring worldwide rights to opakalim and Biohaven’s Kv7 platform, providing $400 million in near-term cash and assuming additional obligations while pivotal RISE3 data remain due in the second half of 2026.